Mantle Cell Lymphoma Education
Mantle cell lymphoma treatment has evolved rapidly with next-generation BTK inhibitors, CAR-T cell therapy, and bispecific antibodies expanding options across lines of therapy. Knowledge Med sessions help physicians navigate these advances through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing mantle cell lymphoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Choosing between intensive and less-intensive frontline approaches based on fitness and biology
- Selecting among BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib)
- Timing CAR-T cell therapy (brexucabtagene autoleucel) in relapsed disease
- Integrating bispecific antibodies and novel combinations after BTK inhibitor failure
What Sessions Cover
Knowledge Med MCL sessions use interactive case simulations to address these topics and more.
- Frontline MCL: intensive vs less-intensive chemoimmunotherapy with maintenance
- BTK inhibitor selection and management of resistance
- CAR-T cell therapy in relapsed MCL: patient selection and real-world outcomes
- Non-covalent BTK inhibitors and emerging treatment strategies
Interactive MCL Sessions
Case Simulations
Work through realistic mantle cell lymphoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key MCL clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Join a MCL Session
Third-party, non-promotional mantle cell lymphoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session